Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Ebitda Margin ExpansionResults View source PDF Explain this filing

LINCOLN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.1%Reaction day

₹529.10

prior close

₹525.10

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+9.4% vs market

Pharmaceuticals peers, median of 148sector+0.2%+8.8% vs sector

On the reaction day the stock moved 9.4 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.9

10m

+5.7

15m

+9.7

30m

+9.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.1-0.3+9.4+0.2+8.8

Next day

+5.8-1.2+7.0-0.4+6.2

+3.4-1.0+4.4-0.2+3.6

+4.6-1.0+5.5-0.1+4.7

+2.6-0.3+2.9+0.2+2.5

+2.6-1.1+3.7-0.6+3.2

+6.4+1.6+4.8+0.2+6.2

15d

+3.4-0.2+3.6-1.2+4.5

+5.1+1.4+3.8-0.9+6.0

-0.0+0.2-0.2-0.9+0.8

-1.3+0.9-2.2-3.7+2.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lincoln Pharmaceuticals reported its Q1 FY26 results on August 7, 2025. Total income grew 7.4% year-on-year to ₹169.34 crore, while revenue from operations rose to ₹154.07 crore from ₹147.28 crore. Net profit jumped 16.9% to ₹27.70 crore compared to ₹23.69 crore in the same quarter last year. EBITDA rose 17.9% to ₹39.08 crore, indicating margin expansion. EPS stood at ₹13.82 versus ₹11.82 in Q1 FY25. The board also approved the re-appointment of the Managing Director and three Whole-Time Directors for five-year terms and appointed a new Secretarial Auditor for FY26-FY30.

Likely market impact

Strong Q1 performance with healthy profit growth and EBITDA margin improvement signals operational strength. The company has zero-term debt and is targeting ₹1,000 crore revenue in 3 years, with FII holding rising to 5.13%. Positive for shareholders, though revenue growth remains in single digits versus the 15-18% annual target.